Using all the existing
data that was available, Andrechek, along with MSU doctoral student Daniel Hollern, analyzed 1,172 mouse mammary tumor samples from 26 different
preclinical models and was able to compile one of the largest databases to
show which strains of mice were best suited to study a particular type of human breast cancer.
[21] In the recently presented FLAURA study, in which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the
preclinical data that
showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastases.